Is the Swedish healthcare system using innovative pharmaceuticals to a lesser extent than other, comparable countries in Europe? What can this depend on? Opticom was contracted by LIF to ask these questions directly to decision makers and Key Opinion Leaders across Europe.
As part of LIF’s seminar “Halkar Sverige efter i användning av moderna läkemedel?” during the 2013 Almedalen week, Project Manager Marijn van der Sluijs will present the main conclusions from a recent international study addressing differences in the use of innovative pharmaceuticals.
Read more about this event on the Almedalen website (in Swedish):